- Home
- EAF vs FENC Comparison
EAF vs FENC Comparison
Compare EAF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | FENC |
|---|---|---|
| Founded | 1886 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.9M | 230.8M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | EAF | FENC |
|---|---|---|
| Price | $9.29 | $7.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $11.75 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 254.0K | 123.9K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | $44,642,000.00 |
| Revenue This Year | $4.25 | $65.12 |
| Revenue Next Year | $12.49 | $41.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $5.65 |
| 52 Week High | $20.32 | $9.92 |
Technical Indicators
Market Signals| Indicator | EAF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 58.77 |
| Support Level | $7.65 | $5.65 |
| Resistance Level | $9.78 | $8.09 |
| Average True Range (ATR) | 0.78 | 0.35 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 76.88 | 92.48 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.